|
|
Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and... |
|
|
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided wit... |
|
|
Recent Developments in the Treatment of Clear Cell, Renal Cell Carcinoma: Essential Insights and Updates for the Healthcare Team
Target Audience
Oncology, Managed care and Specialty Pharmacists and Oncology Nurses/Nurse Practitioners
Program Overview
The goal of this educational initiative is to equip oncology nurse practitioners and nurses, as well as oncology, managed care, and specialty care pharmacists with the knowledge to apply findings from risk scoring systems used to stratify cases of clear cell renal cell carcinoma for treatment selection, differentiate among an expanding array of combination regimens con... |
|
|
Sharing Real-World Experiences with New Rett Syndrome Therapies
Target Audience
The educational design of this activity addresses the needs of neurologists, pediatric neurologists, and specialty NP/PAs involved in the treatment of patients with Rett syndrome.
Program Overview
Integrating newer agents for the treatment of Rett syndrome into clinical practice can be challenging, particularly in community settings. In this activity, an expert panel will convene featuring a neurologist from an International Rett Syndrome Foundation (IRSF)-designated cente... |
|
|
Keeping Up with the Evolving Treatment Landscape for Advanced/Metastatic Gastric/GEJ Cancer: Modeling Center of Excellence Practices
Are you optimally treating your patients with gastric/gastroesophageal junction (GEJ) cancers per the latest evidence on selection of therapies? Despite recent advancements in diagnosis of gastric/GEJ cancer, most cases are detected at advanced stages, resulting in poor outcomes. But advances have identified biomarkers that can offer more precise diagnostic and therapeutic approaches for gastric/GEJ cancer patients. In addition to HER2 and PD-L1 status, microsatellite instability (MSI) status... |
|
|
Autosomal Dominant Polycystic Kidney Disease " Understanding the Disease and Improving Treatment Adherence and Outcome
Target Audience
This activity is designed to meet the educational needs of nephrologists, primary care providers, and providers who care for patients with kidney disease.
Program Overview
In the real-world setting, treatment adherence in patients with autosomal dominant polycystic kidney disease (ADPKD) can be a challenge. This CME program will discuss the diagnosis and management of ADPKD as well as strategies on improving treatment adherence. Patients’ perspectives on how to deal with... |
|
|
Multidisciplinary Team Essentials on CMV Prevention, Surveillance, and Treatment Optimization in the Transplant Setting
The role of the multidisciplinary transplant team has expanded considerably over the past decade to keep pace with advances in the field and to address long-term care of transplant recipients. Despite these advances, breakthrough cytomegalovirus (CMV) infections and development of refractory and resistant CMV infections cause significant complications post-transplant. To lessen patient burden and improve survival outcomes, optimal introduction of anti-CMV drugs, both prophylactically and thera... |
|
|
Making The Call in Lower-Risk MDS Exploring Treatments That Improve Outcomes & Decrease Transfusion Burden
Myelodysplastic syndromes (MDSs) are among the most common hematologic malignancies and are characterized by their risk of progression to acute leukemia. Although patients with lower-risk MDS (LR-MDS) have longer life expectancies compared to those with high-risk disease, their disease course is not without challenges. In fact, symptoms related to anemia are very common in this population and lead to poor quality of life. Fortunately, therapies are now available to treat the anemia associated ... |
|
|
Podcast: Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractor... |
|
|
Treating SCLC in the Relapsed/Refractory Setting: Giving Patients a Voice About Second-Line Therapy
SCLC is aggressive in nature with a high recurrence rate following initial treatment and a propensity to become resistant to conventional therapies. Early detection is critical, but many patients are diagnosed at an advanced stage where prognosis is poor. Progress in the second-line setting offers new hope for improving patient outcomes, but the rapid pace at which these advances are occurring present challenges for effectively integrating novel therapies into patient care. In fact, research s... |
|
|
Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies
In this Hematology Dialogues, Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies, participants will learn about the epidemiology and burden of Epstein-Barr Virus-positive (EBV+) and post-transplant lymphoproliferative disorders (PTLD), differentiate between current and emerging prognostic scoring systems for EBV+ and PTLD to inform treatment decisions, and evaluate the latest clinical evidence of emerging treatment options ... |
|
|
Solving the TED Puzzle: Answering Your Questions on Diagnosis to Decision-Making
Thyroid eye disease (TED) is a complex, autoimmune-mediated, inflammatory disorder of the orbit that presents with a range of symptoms, including ocular pain, dysmotility, and changes in ocular structure and function. The disease severely impacts patients' quality of life, often resulting in persistent discomfort, altered appearance, and impaired vision even after the acute phase subsides. Traditional treatments such as steroids, radiotherapy, and surgery, do not alter the disease's ... |
|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|
|
Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous PBSCs relies on the successful mobilization of hematopoietic stem cells from the bone marrow niche i... |
|
|
Toxicity Management and Symptom Control in Advanced RCC: Playbook Update
STATEMENT OF NEED
Each year, more than 430,000 cases of kidney cancer are diagnosed worldwide. Renal cell carcinoma (RCC), which includes clear cell, papillary, and chromophobe subtypes, is the most common form of kidney cancer. In recent years, the rise of immunotherapy and targeted therapy has contributed to a revolution in the treatment of RCC, with several novel agents and combinations granted approval. While these treatments demonstrate superior efficacy compared with previous standard... |
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and th... |
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re... |
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and th... |
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re... |
|
|
Nursing Management of Oral Mucositis
STATEMENT OF NEED
Oral mucositis (OM) is the inflammation of oral mucosa resulting from cancer therapy and manifesting as atrophy, swelling, erythema, and ulceration (Oronsky et al, 2018). Patients with OM may experience moderate-to-severe pain, difficulty speaking, difficulty eating and drinking, and ulcerations characterized by submucosal hemorrhaging and infection (Bolton, 2021). Due to these crippling effects, OM is considered one of the most debilitating toxicities of cancer therapy (W... |
|
|
EBP/PBE: What Do I Do When There is No Evidence - Dr. Rik Lemoncello
This course provides learners with an understanding of the purpose, procedures, and limitations of evidence-based practice (EBP) in clinical decision-making applied to speech-language pathology. Participants will learn about the important role of practice-based evidence (PBE) and how it complements EBP to support management decisions for individual clients. Practical strategies and resources will be presented so that learners can implement course ideas immediately into practice. |
|
|
iPods, iPads, & iPhones, Oh My! Cognitive Rehab - Dr. Rik Lemoncello
This course is for those professionals working in adult acute and sub-acute rehabilitation settings. (The apps can also apply to those working with preteen/teens in any setting) The course will review accessibility options on an iDevice to support adults with cognitive challenges, describe methods to provide reminders or prompts to adults with memory challenges and describe methods to support attention or executive functioning for adults with cognitive challenges. |
|
|
Managing Speech and Swallowing with Trach/Ventilator Dependence - Rik Lemoncello, PhD, CCC-SLP
This workshop will provide SLPs with important information to understand, assess, and manage speech and swallowing challenges with adult patients who have tracheostomy tubes and/or use ventilators for respiratory support. Dr. Lemoncello will present in a dynamic format with hands-on demonstrations with tracheostomy tubes, ventilator circuits, and speaking valve placement. An adult living with a tracheostomy tube who uses a speaking valve and nighttime ventilator will also share her experiences... |
|
|
Therapy Tidbits – May/June 2017
COURSE ABSTRACT
Therapy Tidbits – May/June 2017 is a 1-hour online continuing education (CE) course comprised of select articles from the May/June 2017 issue of The National Psychologist, a private, independent bi-monthly newspaper intended to keep mental health professionals informed about practice issues. The articles included in this course are:
Advocates in Field of Aging Hear Strong Call to Action - Highlights focus points of the ASA conference in March: critical social and politic... |
|
|
Back to Basics: Typical Swallowing Physiology in Adults - Rik Lemoncello, PhD, CCC-SLP
This course will present current best information to help clinicians learn about typical aspects of oropharyngeal and esophageal swallowing in adults and older adults. This course is ideal for clinicians who need a refresher on typical adult swallowing, and is appropriate for SLP, OT, dietary, nursing, and other medical clinicians involved with interprofessional management of dysphagia. Information covered will include review of sensory and motor control of swallowing, timing and neurological ... |
|
|
Clinical Swallowing Evaluation for Adults - Dr. Rik Lemoncello
This course will present current best information to help clinicians learn about conducting and interpreting a clinical swallowing evaluation for adults in typical medical settings. This course will not discuss specific diagnoses or complex conditions such as tracheostomy/ventilator dependence. This course is ideal for clinicians who need a refresher on the purpose, procedures, observable signs/symptoms, and nature of recommendations that result from a clinical swallowing evaluation for adult ... |
|
|
Mindfulness: The Healing Power of Compassionate Presence
Mindfulness: The Healing Power of Compassionate Presence is a 6-hour online continuing education (CE) course that will give you the mindfulness skills necessary to work directly, effectively, and courageously with your own and your clients' struggles.
Compassion towards others starts with compassion towards self. Practicing mindfulness cultivates our ability to pay intentional attention to our experience from moment to moment. Mindfulness teaches us to become patiently and spaciously aware ... |
|